Comparing how well abrocitinib and dupilumab treat atopic dermatitis signs and symptoms: a plain language summary

Kristian Reich, Jacob P. Thyssen, Andrew Blauvelt, Kilian Eyerich, Weily Soong, Zakiya P. Rice, H. Chih Ho Hong, Norito Katoh, Fernando Valenzuela, Marco Dibonaventura, Tamara A. Bratt, Fan Zhang, Claire Clibborn, Ricardo Rojo, Hernan Valdez, Urs Kerkmann

Publikation: Beitrag in FachzeitschriftÜbersichtsartikelBegutachtung

1 Zitat (Scopus)

Abstract

What is this summary about? Atopic dermatitis (AD, also called atopic eczema) is a skin disease that that can affect a person for a long time and causes red or flaky skin that can be itchy and uncomfortable. Healthcare providers can prescribe medicated creams and ointments to reduce the visible signs and symptoms of AD, but these treatments are not always enough to keep it under control. A new medicine called abrocitinib is taken every day as a tablet. Abrocitinib works by slowing a part of the body's defense mechanism, called immune response, that is not functioning properly in AD. The clinical study described in this plain language summary, called JADE DARE, investigated how well and how safely 26 weeks of treatment with abrocitinib worked in adults with AD compared to an injected medicine, called dupilumab, that is also approved for AD. What were the results? The study showed that abrocitinib was more effective than dupilumab in providing itch relief after 2 weeks. In addition, people who were taking abrocitinib for 4 and 16 weeks experienced greater improvement in the visible skin signs of AD than people who were taking dupilumab. The number of people who had health complaints while taking abrocitinib was similar to the number of people who had health complaints while taking dupilumab. Most of these complaints were minor. What do the results mean? Abrocitinib was more effective than dupilumab in quickly improving the signs and symptoms of moderate or severe AD in people who did not show improvement with prescribed medications like creams or ointments.

OriginalspracheEnglisch
Seiten (von - bis)975-980
Seitenumfang6
FachzeitschriftImmunotherapy
Jahrgang15
Ausgabenummer13
DOIs
PublikationsstatusVeröffentlicht - 1 Sept. 2023
Extern publiziertJa

Fingerprint

Untersuchen Sie die Forschungsthemen von „Comparing how well abrocitinib and dupilumab treat atopic dermatitis signs and symptoms: a plain language summary“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren